Lessons from two trials of mycophenolate mofetil in myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 249-253

  Sanders, Donald B ^a   Siddiqi, Zaeem A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Clinical trial; Muscle Study Group; Myasthenia gravis; Mycophenolate mofetil

Indexed keywords

CHOLINERGIC RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; HUMAN; MYASTHENIA GRAVIS; PROTEIN BLOOD LEVEL;

EID: 45249104185     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.031     Document Type: Conference Paper

References (17)

1. Hauser, R.A. et al. 1998. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 51 : 912 913.
2. Chaudhry, V. et al. 2001. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56 : 94 96.
3. Ciafaloni, E. et al. 2001. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56 : 97 99.
4. Cos, L. et al. 2000. Mycophenolate mofetil (MyM) is safe and well-tolerated in myasthenia gravis (MG). Neurology 54 (Suppl 3 A137.
5. Meriggioli, M.N. et al. 2003. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 61 : 1438 1440.
6. Meriggioli, M.N. et al. 2003. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann. N.Y. Acad. Sci. 998 : 494 499.
7. Ciafaloni, E. 2005. Mycophenolate mofetil and myasthenia gravis. Lupus 14 : S46 S49
8. Muscle Study Group. 2008. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. In press.
9. Jaretzki, A. et al. 2000. Myasthenia gravis. Recommendations for clinical research standards. Neurology 55 : 16 23.
10. Barohn, R.J. et al. 1998. Reliability testing of the quantitative myasthenia gravis score. Ann. N.Y. Acad. Sci. 841 : 769 772.
11. Tindall, R.S.A. et al. 1987. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N. Engl. J. Med. 316 : 719 724.
12. Tindall, R.S.A. et al. 1993. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. N.Y. Acad. Sci. 681 : 539 551.
13. Lachin, J.M. 1981. Introduction to sample size determination and power analysis for clinical trials. Controlled Clin. Trials 2 : 93 113.
14. Sanders, D.B. et al. 2003. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann. N.Y. Acad. Sci. 998 : 440 444.
15. Wolfe, G.I. et al. 1999. Myasthenia gravis activities of daily living profile. Neurology 52 : 1487 1489.
16. Sanders, D.B. et al. 2008. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. In press.
17. Meriggioli, M.N. & J. Rowin. 2003. Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J. Clin. Neurophysiol. 20 : 382 385.